Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.

Abstract excerpt

Systemic mastocytosis is a malignant neoplasm classically driven by the KIT D816V mutation. Due to the range of clinical outcomes in these patients, the diagnosis and subclassification of the disease is complex but critical to understanding management, prognosis and therapeutic approaches. In those with non-advanced systemic mastocytosis, treatment decisions are tailored towards symptom improvement, whereas in...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• Disease Management
• Mastocytosis, Systemic
• Molecular Targeted Therapy
• Mutation